This letter was shown to the authors, one of whom responds as follows:

Sir,—It is true that the positive predictive accuracy of all the available tests for predicting the arrhythmic death in patients after myocardial infarction is low and that more specific tests are needed. Because our study was cross sectional it cannot give information on the predictive accuracy of an occluded infarct-related artery. However, it was the first study to show the beneficial effects of perfusion of an old infarct scar on the electrophysiological substrate. We agree that in this type of cross sectional comparison it is difficult to achieve 1:1 matching of all the factors that may influence arrhythmogenesis. None the less the study was specifically designed to match the patient groups for ejection fraction, wall motion abnormalities (including presence of ventricular aneurysm), and number of previous infarctions (tables 1 and 2).

No conclusions about the benefits of revascularisation can be based on the data of our study, but we hope that a randomised prospective trial that is underway will give insights into the potential beneficial effects of angioplasty of the occluded infarct artery on the arrhythmogenic substrate.

HEIKKI V HUIKURI
Division of Cardiology
Department of Medicine
Oulu University
Central Hospital,
90200 Oulu
Finland


Non-surgical ablation of the ventricular septum for the treatment of hypertrophic cardiomyopathy

Sir,—We read with interest Professor Oakley’s erudite review of the natural course and treatment of hypertrophic cardiomyopathy.1 Sadly, she regards the development of surgical ablation of the ventricular septum at our hospital as an ingenious but unimportant endeavour. She observes that symptoms, gradients, and outlook are unrelated in hypertrophic cardiomyopathy; that surgical septal ablation does not improve outcome and may impair overall left ventricular function; and finally that the natural course of hypertrophic cardiomyopathy is towards a reduction in outflow tract obstruction with time as left ventricular impairment and dilatation progress. Undoubtedly, the degree of obstruction of the outflow tract does not correlate well with either symptomatic status or outlook within populations of patients with hypertrophic cardiomyopathy. None the less, when an individual patient has a large outflow gradient and symptoms that correlate with such obstruction—namely, exertional angina, dyspnoea, and syncope—an association between outflow tract obstruction and symptoms seems beyond any doubt. Furthermore, there is evidence that these symptoms are improved by manoeuvres that reduce the obstruction,2 including our new technique.1 As there is no prospective randomised evidence to suggest that surgical relief of outflow tract obstruction either prolongs or shortens life, it is important that both surgical and non-surgical myocardial reduction are performed for the palliation of symptoms. We have not suggested that survival benefits of any of non-surgical septal—although we hope it does.

In any cardiomyopathic process, maintaining as many normally functioning myocytes as possible is clearly desirable, but the evidence that myometectomy significantly improves overall left ventricular function is slim. In the series mentioned in the editorial,3 the evidence for such impairment was a rise in end diastolic diameter from a mean of 4.5 to 5.1 cm over mean follow up of 8–9 years. Fractional shortening was unchanged (41% v 39%). The evidence quoted from Sprioto et al’s study4 that the natural course of hypertrophic cardiomyopathy is a progressive, inevitable decline in overall left ventricular function, with a consequent reduction in gradient is also not robust: in Sprioto’s series of patients with severe hypertrophic cardiomyopathy, those who had normal ejection fraction at baseline (n = 54) had a mean rise of just 1 mm in end diastolic diameter over follow up and none developed clinical heart failure. The 13 patients with ejection fractions of less than 50% had a scarcely impressive rise of 5 mm in end diastolic diameter and only one patient in the series had a definite reduction in gradient with time. We cannot rely on time and the natural course of the disease to rid all of our patients of their worrisome and incapacitating left ventricular outflow tract obstruction.

The primary goal in the treatment of hypertrophic cardiomyopathy is clearly the development of strategies known to prolong life and prevent sudden death, but the provision of symptomatic relief for patients can not be ignored. Professor Oakley concludes that “the extreme clinical and genetic heterogeneity of the disease has prevented any prospective randomised trials to assess the effect on outcome of most forms of treatment.”4 We hope that she recognises that this clinical heterogeneity encompasses a minority of patients with large outflow gradients and corresponding disabling symptoms. We feel our efforts to provide symptomatic relief for this subgroup by means of non-surgical septal reduction are worthwhile, even though the long term effects on outcome may not be known for many years.

CHARLES KNIGHT
ULRICH SIGWART
Royal Brompton Hospital,
Sydney Street,
London SW3 6NP


This letter was shown to the authors, who reply as follows:

Sir,—I thank Dr Knight and Dr Sigwart for summarising my editorial so well in the first paragraph of their letter and of course I agree that progressive decline in overall left ventricular function is not inevitable. Some have mild disease and some die early but others suffer gradual loss of systolic efficiency. Only a small increase in residual volume heralds the onset of low output failure because of the marked diastolic impairment in these patients whose ventricles do not readily dilate. The natural progression of myocyte fall-out, whether due to the myopathy or to ischaemia, will have been accelerated by “myocardial reduction” in the name of therapy. We shall see.

CELIA M OAKLEY
Hamershmith Hospital,
Dr Cave Road,
London W12 ONN

A wide health remit for aspirin

Sir,—It is widely recognised that aspirin helps to reduce the risk of certain cardiovascular diseases. More recently, good evidence has indicated that aspirin can also help to reduce the risk of certain gastrointestinal cancers.1 We write to ask whether cardiologists who frequently prescribe aspirin have any “ dormant” data on the risk of cancer. I am also interested in collaborating with any colleagues who might be conducting randomised trials of aspirin intervention. I would be able to advise on the measurement of wider health gains relating to a reduced risk of cancer.

GARETH MORGAN
Pharmaceutical Development,
West Glamorgan Health Authority,
41 High Street,
Swansea SA1 1LZ


NOTICE

An international workshop on Recent Developments in Cardiac Surgery (video assisted demonstrations on left ventricular reduction and minimally invasive coronary surgery) will be held on the 3 and 4 October 1996 at the Hilton National Hotel, Bristol, United Kingdom. For further information please fax: +44-117-9299737 (Mrs N J Merrell).
Non-surgical ablation of the ventricular septum for the treatment of hypertrophic cardiomyopathy
Charles Knight, Ulrich Sigwart and Celia M Oakley

*Heart* 1996 76: 92
doi: 10.1136/hrt.76.1.92-a

Updated information and services can be found at:
http://heart.bmj.com/content/76/1/92.2.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/